clinical trial · NCT05498597
AMT-151 in Patients With Selected Advanced Solid Tumours
Advanced Solid TumorAdvanced CancerAdvanced CarcinomaOvarian CancerOvarian CarcinomaOvarian Epithelial CancerOvarian Endometrioid AdenocarcinomaEndometrial CancerAMT-151
brief summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.
started
Jan 25, 2023
primary completion
Jan 1, 2024
completion
Oct 30, 2024
last updated
Oct 19, 2023
official title
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol